Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | RAD52 | P43351 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 9/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 9/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.64 |
| ▸ | HTR1D | P28221 | 4/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.64 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.64 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.64 |
| ▸ | HTR1B | P28222 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1322022 | 0.99 | LMNA (0.69) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7201422 | 0.99 | LMNA (0.69) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Chloroethylclonidine SCHEMBL18154646 | 0.81 | CYP2D6 (1.00) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| SCHEMBL11180812 | 0.81 | ADRA2A (0.76) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| SCHEMBL24658874 | 0.78 | ADRA2A (0.71) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Pi-Clonidine SCHEMBL563884 | 0.78 | ADRA2A (1.00) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Apraclonidine SCHEMBL34128 | 0.78 | ADRA2A (1.00) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| SCHEMBL11761437 | 0.78 | ADRA2C (0.71) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| SCHEMBL10414088 | 0.78 | ADRA2A (0.71) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Apraclonidine SCHEMBL1002875 | 0.77 | BLM (1.00) | CYP2D6TSHRNFKB1HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034510-A1 | ADRENERGIC ANTAGONISTS FOR USE IN A METHOD FOR TREATING CEREBRAL EDEMA OR A BRAIN INJURY | UNIVERSITY OF ROCHESTER (US) | 2025-02-13 | — | — | WO | claimed |
| US-10918629-B2 | Method for treating lymphedema | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2021-02-16 | — | — | US | claimed |
| US-20200383978-A1 | METHODS FOR INDUCING PUPIL DILATION | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2020-12-10 | — | — | US | claimed |
| EP-3706868-A1 | METHODS FOR INDUCING PUPIL DILATION | The Regents of the University of Colorado, a Body Corporate (US) | 2020-09-16 | — | — | EP | claimed |
| EP-3407976-A1 | COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTS | Levation Pharma Ltd. (US) | 2018-12-05 | — | — | EP | claimed |
| CN-108883308-A | Compositions and uses of alpha-adrenergic agents | 利维申制药有限公司 | 2018-11-23 | — | — | CN | claimed |
| US-20170333412-A1 | METHOD FOR TREATING LYMPHEDEMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-23 | — | — | US | claimed |
| WO-2017132410-A1 | COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTS | LITVACK FRANK (US) | 2017-08-03 | — | — | WO | claimed |
| EP-2731606-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | Allergan, Inc. (US) | 2014-05-21 | — | — | EP | claimed |
| CN-103796652-A | Gel compositions of oxymetazoline and methods of use | ALLERGAN INC | 2014-05-14 | — | — | CN | claimed |
| US-20130079379-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | ALLERGAN, INC. (US) | 2013-03-28 | — | — | US | claimed |
| WO-2013010032-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | ALLERGAN, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| US-7550466-B2 | Alpha and/or β-adrenergic antagonists and agonists to treat pain | SUN HEALTH RESEARCH INSTITUTE (US) | 2009-06-23 | — | — | US | claimed |
| US-7462618-B2 | Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists | SUN HEALTH RESEARCH INSTITUTE (US) | 2008-12-09 | — | — | US | claimed |
| US-20080153830-A1 | ALPHA AND/OR BETA-ADRENERGIC ANTAGONISTS AND AGONISTS TO TREAT PAIN | SUN HEALTH RESEARCH INSTITUTE | 2008-06-26 | — | — | US | claimed |
| EP-1109542-A4 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-03-26 | — | — | EP | claimed |
| US-20050049256-A1 | Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists | SUN HEALTH RESEARCH INSTITUTE | 2005-03-03 | — | — | US | claimed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | claimed |
| EP-1109542-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079379-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | CUTA, PDE3A, PTGIS | CYP2D6 3309/4885TSHR 1159/4885NFKB1 2561/4885 |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | ADRB1, ADRB3, ADRA1D | CYP2D6 449/4885TSHR 1408/4885NFKB1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.